×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SABS – sab biotherapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SABS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/9
06:10 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Low
Report
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
1/7
08:00 am
sabs
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
Medium
Report
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
1/7
02:01 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Medium
Report
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
1/6
08:00 am
sabs
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/23
07:06 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
Low
Report
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
12/19
07:02 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
Low
Report
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
12/18
08:05 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
Low
Report
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
12/18
08:00 am
sabs
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
Low
Report
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/12
04:48 pm
sabs
Form 8-K SAB Biotherapeutics, For: Jan 12
Medium
Report
Form 8-K SAB Biotherapeutics, For: Jan 12
1/8
06:02 am
sabs
Form EFFECT SAB Biotherapeutics,
Low
Report
Form EFFECT SAB Biotherapeutics,
1/7
04:41 pm
sabs
Form 4 SAB Biotherapeutics, For: Jan 05 Filed by: Jain Rita
Low
Report
Form 4 SAB Biotherapeutics, For: Jan 05 Filed by: Jain Rita
1/7
04:40 pm
sabs
Form 4 SAB Biotherapeutics, For: Jan 05 Filed by: ZACCARDELLI DAVID
Low
Report
Form 4 SAB Biotherapeutics, For: Jan 05 Filed by: ZACCARDELLI DAVID
1/7
04:36 pm
sabs
Form 3 SAB Biotherapeutics, For: Jan 05 Filed by: Jain Rita
Low
Report
Form 3 SAB Biotherapeutics, For: Jan 05 Filed by: Jain Rita
1/7
04:35 pm
sabs
Form 3 SAB Biotherapeutics, For: Jan 05 Filed by: ZACCARDELLI DAVID
Low
Report
Form 3 SAB Biotherapeutics, For: Jan 05 Filed by: ZACCARDELLI DAVID
1/7
08:30 am
sabs
Form 8-K SAB Biotherapeutics, For: Jan 05
Medium
Report
Form 8-K SAB Biotherapeutics, For: Jan 05
12/30
10:09 am
sabs
Form S-3 SAB Biotherapeutics,
Medium
Report
Form S-3 SAB Biotherapeutics,
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: